OBJECTIVES:Autism spectrum disorders (ASDs) have core impairments in social communication as well as the presence of repetitive, stereotypic behaviors and restricted interests. Older adolescents and young adults are particularly impacted by these deficits. Preclinical data implicate glutamatergic dysfunction in the pathophysiology of ASDs. D-Cycloserine (DCS), a partial glycineB agonist at the N-methyl-D-aspartic acid receptor site, has been shown to improve sociability in mouse models and a small human study. The sensitivity of the obligatory glycineB co-agonist binding site may change with daily administration of DCS as a result of agonist-induced desensitization. The efficacy of a "pulsed" once-weekly administration versus "daily" administration of DCS was compared. METHODS: Males and females, ages 14 to 25 years, with a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Text Revision diagnosis of an ASD were enrolled in a double-blind, randomized 10-week trial consisting of 8 weeks of active drug with either weekly or daily administration of 50 mg of DCS followed by a 2-week follow-up visit. RESULTS: For the purposes of this study, no statistical or clinical differences existed between the 2 dosage groups on the Aberrant Behavior Checklist subscale 3, which measures stereotypies/repetitive movements. When combining groups, a statistically significant decrease of 37% was found from baseline to week 8 when study drug was completed using a linear mixed effects model (P = 0.003). CONCLUSIONS:D-Cycloserine was shown to be effective in improving stereotypic symptoms in older adolescents and young adults with ASDs measured by the Aberrant Behavior Checklist subscale 3. In addition, DCS was safe and well tolerated.
RCT Entities:
OBJECTIVES:Autism spectrum disorders (ASDs) have core impairments in social communication as well as the presence of repetitive, stereotypic behaviors and restricted interests. Older adolescents and young adults are particularly impacted by these deficits. Preclinical data implicate glutamatergic dysfunction in the pathophysiology of ASDs. D-Cycloserine (DCS), a partial glycineB agonist at the N-methyl-D-aspartic acid receptor site, has been shown to improve sociability in mouse models and a small human study. The sensitivity of the obligatory glycineB co-agonist binding site may change with daily administration of DCS as a result of agonist-induced desensitization. The efficacy of a "pulsed" once-weekly administration versus "daily" administration of DCS was compared. METHODS: Males and females, ages 14 to 25 years, with a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Text Revision diagnosis of an ASD were enrolled in a double-blind, randomized 10-week trial consisting of 8 weeks of active drug with either weekly or daily administration of 50 mg of DCS followed by a 2-week follow-up visit. RESULTS: For the purposes of this study, no statistical or clinical differences existed between the 2 dosage groups on the Aberrant Behavior Checklist subscale 3, which measures stereotypies/repetitive movements. When combining groups, a statistically significant decrease of 37% was found from baseline to week 8 when study drug was completed using a linear mixed effects model (P = 0.003). CONCLUSIONS:D-Cycloserine was shown to be effective in improving stereotypic symptoms in older adolescents and young adults with ASDs measured by the Aberrant Behavior Checklist subscale 3. In addition, DCS was safe and well tolerated.
Authors: Michael G Aman; William Kasper; George Manos; Suja Mathew; Ronald Marcus; Randall Owen; Raymond Mankoski Journal: J Child Adolesc Psychopharmacol Date: 2010-10 Impact factor: 2.576
Authors: Stephen I Deutsch; Gerald J Pepe; Jessica A Burket; Erin E Winebarger; Amy L Herndon; Andrew D Benson Journal: Brain Res Date: 2011-12-29 Impact factor: 3.252
Authors: Sylvie Goldman; Cuiling Wang; Miran W Salgado; Paul E Greene; Mimi Kim; Isabelle Rapin Journal: Dev Med Child Neurol Date: 2009-01 Impact factor: 5.449
Authors: Tatiana M Kazdoba; Prescott T Leach; Mu Yang; Jill L Silverman; Marjorie Solomon; Jacqueline N Crawley Journal: Curr Top Behav Neurosci Date: 2016
Authors: Jessica A Burket; Andrew D Benson; Amy H Tang; Stephen I Deutsch Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2015-02-20 Impact factor: 5.067
Authors: Allan V Kalueff; Adam Michael Stewart; Cai Song; Kent C Berridge; Ann M Graybiel; John C Fentress Journal: Nat Rev Neurosci Date: 2015-12-17 Impact factor: 34.870
Authors: Steven D Hicks; Richard Uhlig; Parisa Afshari; Jeremy Williams; Maria Chroneos; Cheryl Tierney-Aves; Kayla Wagner; Frank A Middleton Journal: Autism Res Date: 2018-08-14 Impact factor: 5.216